Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3 - Implementing MCED Testing in Clinical Practice Through Case Studies

Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3 - Implementing MCED Testing in Clinical Practice Through Case Studies is organized by i3 Health.

Dates Available:
August 20, 2024 - August 19, 2025

Description:
Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application.

In Module 3 of our CME microlearning series, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, will explore the practical implementation of multicancer early detection (MCED) tests into clinical practice, offering valuable insights into how these innovations could transform cancer screening and improve patient outcomes. Start the activity now!

Statement of Need:
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States (ACS, 2024; Pinsky & Berg, 2012; USPSTF, 2024). Multicancer early detection (MCED) is a novel form of blood-based cancer screening testing that can screen for multiple cancers simultaneously (ACS, 2024). Numerous questions need to be addressed as MCED is incorporated into practice, such as determining cost and insurance coverage, identifying individuals who are suitable candidates, and counseling patients regarding testing options, results, and next steps after receiving a positive or negative result (Kim et al, 2022; Chambers et al, 2023). In Module 3 of this activity, Dr. Charles Vega, Clinical Professor of Family Medicine in the School of Medicine at the University of California, Irvine, will discuss the practical application of MCED testing, the process for ordering and follow-up of results, and individual cases underscoring the optimal use of MCED testing in clinical practice.

Learning Objectives:
Upon completion of this activity, participants should be able to

• Differentiate MCED tests from other blood-based screening tests
• Explain how MCED testing complements existing screening and diagnostic methods in gastrointestinal, gynecologic, and hematologic cancers
• Assess current and emerging data supporting the use of MCED tests in clinical practice
• Discuss tactics to promote the widespread adoption of cancer screening in the community
• Apply practical tools and strategies for integrating the latest cancer screening technologies into the clinical workflow